Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
2
Pipeline Programs
4
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Chia Tai TianQing Pharmaceutical GroupChina - Lianyungang
1 programTQC2731 injectionPHASE_31 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2025
2026
2027
Chia Tai TianQing Pharmaceutical GroupTQC2731 injection
Longbio PharmaLP-003 Injection
Clinical Trials (2)
Total enrollment: 396 patients across 2 trials
Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps
Start: Sep 2025Est. completion: Sep 2027246 patients
Phase 3Recruiting
A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Start: Jan 2026Est. completion: Sep 2027150 patients
Phase 2Not Yet Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 396 patients
4 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.